Results from a late-stage clinical trial released late Friday by the drug maker CytoDyn showed its experimental antibody leronlimab failed to improve the survival of patients hospitalized with severe, life-threatening cases of Covid-19.
Instead of acknowledging the negative outcome of the Phase 3 clinical trial, however, CytoDyn issued two statements over the weekend claiming results spun from a small slice of patients were positive and warranted approval as a treatment for Covid-19.
“We believe these results are the best results ever achieved for this population in a Phase 3 clinical trial,” said CytoDyn CEO Nader Pourhassan, in the first statement released Friday evening just before 6 pm ET. The company is working with regulators to “expedite” the approval of leronlimab to treat Covid-19, he added.
About the Author Reprints
